Monash IVF Rejects $0.90 Takeover Bid as Too Low Under New CEO
Monash IVF has rejected a $0.90 per share takeover proposal from a consortium comprising Genesis Capital Investment Management and WHSP Holdings (Soul Patts). The Board unanimously determined that the revised offer undervalues the company and is not in the best interests of shareholders.
Board unanimously rejects $0.90 per share offer
The consortium’s proposal, delivered via a Scheme of Arrangement, was described as the “highest amount the Consortium is prepared to offer” absent a competing bid. The offer was conditional and non-binding, with a deadline of close of business 21 April 2026.
Following an accelerated internal planning cycle and consultation with financial and legal advisers, the Board concluded the proposal does not reflect the company’s intrinsic value. The decision was made after considering the company’s strategy, internal projections, and current market dynamics.
The Board remains open to change of control discussions at higher valuations but will only progress proposals that represent compelling value for shareholders. Genesis Capital and Soul Patts first approached the company with a lower offer before submitting this revised proposal on 13 April 2026.
When big ASX news breaks, our subscribers know first
Why the board said no
The Board cited three key reasons for rejecting the consortium’s $0.90 per share offer:
-
Valuation discount to comparable transactions – The Offer Price sits at a substantial discount to recent IVF acquisitions in the Australian market, suggesting the proposal does not reflect fair value based on sector benchmarks.
-
Confidence in new leadership – The recent appointment of Dr Victoria Atkinson as Chief Executive Officer follows a period of operational instability. The Board expressed strong support for Dr Atkinson’s strategy to return stability and growth to Monash IVF.
-
Shareholder feedback – Non-consortium shareholders provided input on the proposal, with feedback supporting the Board’s assessment that the offer undervalues the business.
Richard Davis, Chairman
“The Board, in consultation with its advisers, has formed the view that the revised Proposal in its current form undervalues the Company. The Board is supportive of Dr Victoria Atkinson and looks forward to the execution of her strategy to bring stability and growth to Monash IVF.”
The Board’s rejection signals confidence that the company’s standalone prospects under new management justify a higher valuation than the consortium is willing to pay.
What is a Scheme of Arrangement?
A Scheme of Arrangement is a formal court-supervised process used in Australia to effect a company takeover or restructure. It requires approval from shareholders at a scheme meeting, typically needing 75% of votes cast by number and a majority by headcount. The transaction must also receive court approval before it can proceed.
Because the Board has rejected the Genesis Capital and Soul Patts proposal, no scheme process will commence unless a new offer emerges. Board support is typically essential for a scheme to succeed, as directors control the flow of information to shareholders and set the narrative around value.
Without board endorsement, bidders face significant hurdles in convincing shareholders to vote in favour of a transaction. The rejection effectively halts the current proposal unless the consortium returns with improved terms or a competing bidder emerges.
The consortium’s position
Genesis Capital and Soul Patts stated the $0.90 per share offer represents the highest price they are prepared to pay, absent a competing proposal emerging for all or a material part of Monash IVF. The consortium described the proposal as “best and final” under current circumstances.
The offer was conditional and non-binding, meaning it was subject to due diligence, financing conditions, and other customary requirements. With the Board’s rejection announced on 20 April 2026, the consortium’s 21 April 2026 deadline has effectively passed without agreement.
The next major ASX story will hit our subscribers first
What happens next for shareholders
Shareholders should be aware of the following:
- No action required – Shareholders do not need to take any steps in relation to the rejected proposal.
- No certainty of transaction – There is no guarantee that ongoing discussions with the consortium will result in a deal.
- Board open to higher offers – The company remains receptive to change of control proposals at valuations the Board considers compelling.
- Continuous disclosure applies – Monash IVF will update the market on material developments as required under ASX listing rules.
The Board’s decision to reject the $0.90 offer does not close the door to merger and acquisition activity. Shareholders may benefit if a competing bidder emerges or if Genesis Capital and Soul Patts return with an improved proposal that addresses the Board’s valuation concerns.
The company’s willingness to engage on higher offers suggests management views the standalone business case under Dr Atkinson’s leadership as capable of delivering shareholder value in excess of the current proposal. Investors should monitor ASX announcements for updates on any renewed takeover interest or strategic developments.
Want the Next Healthcare Takeover in Your Inbox?
Join 20,000+ investors receiving FREE ASX Healthcare alerts within minutes of release, complete with expert analysis on M&A activity, board rejections, and takeover bids. Click the “Free Alerts” button at Big News Blast to get breaking news and in-depth coverage the moment it hits the market.